BioLife Solutions, Inc. Announces Second Quarter 2017 Financial Results
BOTHELL, Wash., Aug. 10, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today reported operational highlights and financial results for the three and six months ended June 30, 2017.
Revenue from biopreservation media product sales reached a new high of $2.6 million in the second quarter of 2017, an increase of 29% over the same period in 2016. This was the eighth consecutive quarter of record revenue. Revenue for the six months ended June 30, 2017 was $4.9 million, or 28% above 2016. Revenue growth for both periods was driven by sales of CryoStor® and HypoThermosol® clinical grade biopreservation media products to the regenerative medicine segment and BioLife's worldwide distributor network.
Revenue from biopreservation media product sales reached a new high of $2.6 million in the second quarter of 2017, an increase of 29% over the same period in 2016. This was the eighth consecutive quarter of record revenue. Revenue for the six months ended June 30, 2017 was $4.9 million, or 28% above 2016. Revenue growth for both periods was driven by sales of CryoStor® and HypoThermosol® clinical grade biopreservation media products to the regenerative medicine segment and BioLife's worldwide distributor network.